|Trade names||Apidra, Apidra SoloStar|
|Drug class||Insulin (rapid acting)|
|Main uses||Type 1 and type 2 diabetes|
|Side effects||Low blood sugar, pain at the site of injection|
|Chemical and physical data|
|Molar mass||5822.64 g·mol−1|
Insulin glulisine, sold under the brand name Apidra, is a rapid acting insulin used to treat type 1 and type 2 diabetes. It is given by injection under the skin between 15 minutes before to 20 minutes after starting a meal. It may also be used by injection into a vein. It is generally used with a long acting insulin.
Common side effects include low blood sugar and pain at the site of injection. Other side effects may include allergic reactions, low potassium, and lipodystrophy. It is made by recombinant DNA techniques.
Insulin glulisine was approved for medical use in the United States and Europe in 2004. In the United Kingdom 300 units costs the NHS about £6 as of 2021. In the United States this amount costs just over 100 USD.
Insulin glulisine is indicated for the treatment of diabetes mellitus.
The typical dose of all insulins in type 1 DM is 0.2 to 1 unit/kg per day.
It differs from human insulin in that the amino acid asparagine at position B3 is replaced by lysine and the lysine in position B29 is replaced by glutamic acid.
It was developed by Sanofi-Aventis.
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 1.6 1.7 1.8 1.9 "Insulin Glulisine Monograph for Professionals". Drugs.com. Archived from the original on 8 August 2020. Retrieved 26 November 2021.
- ↑ 2.0 2.1 2.2 2.3 2.4 2.5 "Apidra EPAR". European Medicines Agency (EMA). Archived from the original on 10 October 2020. Retrieved 7 October 2020.
- ↑ 3.0 3.1 "Insulin glulisine Use During Pregnancy". Drugs.com. 6 April 2020. Archived from the original on 4 December 2020. Retrieved 21 September 2020.
- ↑ 4.0 4.1 4.2 "Apidra- insulin glulisine injection, solution Apidra SoloStar- insulin glulisine injection, solution". DailyMed. 6 December 2019. Archived from the original on 25 March 2021. Retrieved 21 September 2020.
- ↑ BNF 81: March-September 2021. BMJ Group and the Pharmaceutical Press. 2021. p. 754. ISBN 978-0857114105.
- ↑ "Apidra Prices, Coupons & Savings Tips". GoodRx. Archived from the original on 11 December 2021. Retrieved 26 November 2021.
- ↑ "Apidra (insulin glulisine) injection, solution". DailyMed. Archived from the original on 2010-06-15. Retrieved 2020-12-02.
- ↑ Jasek W, ed. (2007). Austria-Codex (in Deutsch) (2007/2008 ed.). Vienna: Österreichischer Apothekerverlag. ISBN 978-3-85200-181-4.
- "Insulin glulisine". Drug Information Portal. U.S. National Library of Medicine. Archived from the original on 2020-10-24. Retrieved 2020-12-02.
- Pages using duplicate arguments in template calls
- CS1 Deutsch-language sources (de)
- Drugs with non-standard legal status
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drug has EMA link
- Drugboxes which contain changes to verified fields
- Drugboxes which contain changes to watched fields
- Articles with changed CASNo identifier
- Chemicals that do not have a ChemSpider ID assigned
- Insulin receptor agonists
- Insulin therapies
- All stub articles
- Gastrointestinal system drug stubs